BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Friday, September 25, 2026
📌TL;DR
GRAL closed at $125.21 Thursday, up 15.4% from its last traded price, in the first session after Wednesday's panel vote; the stock never traded on panel day, and the week's gain from Friday's $80.77 stands at 55.0% (our arithmetic).
Viking priced an upsized $500 million raise before the open, 7,857,143 shares at $35.00 plus $225.0 million of 2.00% convertible notes, and VKTX closed down 11.8% at $36.75.
Eli Lilly signed a five target discovery collaboration with Beijing based InnoCare: up to $100 million upfront and near term, up to approximately $3.25 billion in milestones, per InnoCare's release.
The FDA approved Elevar's Lyrfigtu (lirafugratinib) for FGFR2 rearranged bile duct cancer on September 23, the first novel cancer drug from a Korean company per Fierce Pharma, on a 46% response rate in REFOCUS.
Acadia's remlifanserin missed its Phase 2 Alzheimer's psychosis primary at p equal to 0.0603; both Phase 3 studies continue, and ACAD closed down 12.8%.
FDA nominee Heidi Overton called the MMR vaccine and mifepristone safe and effective at her Senate hearing, and AbbVie presents full CERVINO etentamig data today at the IMS meeting.
⚡ Executive Takeaway
We owe you a correction on our own frame. Going into the vote we treated Grail's 34% pre panel rally as the outcome already paid for, and the open question as how much of it survived a mixed vote. Thursday answered: the first session that could trade the result added another 15.4%. The rally had not prepaid the vote. It had priced the base case, and settlement priced something else, the removal of the tail.
That is the transferable mechanic. A halt does not delay price discovery, it splits it in two. Before a binary event, the tape can only price the expected outcome; it cannot pay for certainty it does not have. When trading resumes with the outcome known, the discount for the scenario that did not happen comes out of the price separately, and it is worth real money, in this case 15.4% on top of a 34% run. The next time a stock is halted through a binary and the crowd says the result is priced in, remember that only the forecast is priced in. Certainty settles later, at its own price. Today the gauntlet's third date lands: AbbVie's withheld CERVINO medians come due in front of a room full of myeloma doctors, and we grade the full week Sunday night.
🧬 Diagnostics
The first session that could trade the vote paid up, not out. GRAL | GH
GRAL settled Thursday at $125.21, up 15.4% from the $108.52 last trade that preceded Wednesday's session long halt, taking the gauntlet week gain to 55.0% from Friday's $80.77, our arithmetic throughout. Canaccord Genuity reiterated its Buy after the vote, per Investing.com, printed here as context rather than cause. The FDA's final decision on the first multi cancer early detection PMA is expected in the coming months, per Grail, and after a 6 to 4 effectiveness vote the fight that matters is the label text, specifically whether the phrase early detection survives it. Guardant closed flat a second straight session at $176.45; the market is treating this as Galleri's vote, not the category's.
💰 Capital Markets
Viking converted Tuesday's rally into half a billion dollars of balance sheet inside 48 hours. VKTX | ETRA
Before Thursday's open Viking priced an upsized $500 million raise: 7,857,143 shares at $35.00, about 16% below Wednesday's close, plus $225.0 million of 2.00% convertible notes due 2032 converting near $50.75, a 45% premium, per the pricing release. Estimated combined net proceeds run about $476.2 million before underwriter options, our arithmetic from the release figures, earmarked for VK2735 and VK3019. VKTX gave back 11.8% to $36.75 and still sits above its pre data level. The other end of the same window: Electra fell 6.7% to $11.82, a new low 21.2% below its $15.00 issue price, with the greenshoe clock running. The financing window is open by stage and de risking, not by sector.
🌏 China
Lilly went shopping in Beijing the same day Boehringer sold Shanghai at scrap value. LLY
Lilly's InnoCare pact covers up to five targets in cancer and autoimmune disease for up to $100 million upfront and near term plus up to approximately $3.25 billion in milestones and single digit royalties, per InnoCare's release; InnoCare discovers, Lilly develops and sells. Hours earlier, Shanghai's Henlius licensed conditionally activated T cell engagers from California's Amberstone in a deal worth up to $440 million, upfront undisclosed, per Fierce. And Boehringer Ingelheim agreed to sell its Shanghai biologics CDMO, 6,000 liters of commercial capacity against $66 million of registered capital, to Raas Blood Products for up to about $3 million, after a $38.5 million loss in 2025, per Fierce Pharma. Discovery science there commands global capital; manufacturing capacity is deflating. Senator Todd Young spent the same day arguing for a federal biotech coordinator with the president's ear.
🎗️ Oncology
Korean biotech got its first FDA approved novel cancer drug. Elevar (HLB Group)
The FDA approved Lyrfigtu (lirafugratinib) on September 23 for previously treated cholangiocarcinoma with an FGFR2 fusion or other rearrangement, on a 46% response rate and 11.8 month median duration of response in the 116 patient single arm REFOCUS study, per the agency's approval notice. Per Fierce Pharma it is the first novel cancer drug from a Korean company to clear the FDA; Elevar, HLB Group's US subsidiary, bought the covalent FGFR2 selective inhibitor from Relay in 2024 for $75 million upfront, and the approval lands after three complete response letters on its separate liver cancer combination. A European filing went in September 15, with US availability expected this year.
🧠 Neuro
Acadia's near miss was clean enough to keep the Phase 3 bet alive. ACAD
Remlifanserin improved hallucinations and delusions scores by 12.6 points versus 10.4 on placebo at week 6, p equal to 0.0603, just outside significance, in the Phase 2 portion of RADIANT in Alzheimer's disease psychosis, per Acadia's release. The key severity secondary was nominally significant at 0.0077, adverse events matched placebo with no QT signal, and Acadia is continuing both Phase 3 studies while dropping the 30 mg dose and enriching enrollment toward higher baseline severity, a tweak that lifts the retrospective effect size to 0.33, per Fierce. ACAD closed down 12.8% at $22.18, the readout as same day context. A near miss with clean safety in a field with one approved drug, Acadia's own, is a live program priced like a dead one.
🏛️ Policy
Overton said the science words and left the independence question open.
At her Senate HELP hearing Thursday, FDA commissioner nominee Heidi Overton called the MMR vaccine and mifepristone safe and effective, citing the agency's own determinations, while repeatedly declining to say the president was wrong on vaccines, per Fierce and Endpoints. She backed swifter clinical trial designs, the line most relevant to sponsors. Senators from both parties, Cassidy on statutory vaccine obligations and Murphy on tobacco decisions, pressed the same underlying question of whether the agency's scientific calls survive political pressure, and did not get a direct answer. The committee vote is not yet scheduled.
📋 Quick Hits
Merck said remigromig matched Lucentis on visual acuity in the Phase 2b/3 Brunello DME trial while disclosing higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and discontinuations, per BioPharma Dive; every number is withheld until October 10, so we hold them too.
Thursday's tape repairs: XENE rebounded 4.1% and CLDX printed its first up session since its readout, up 1.2% with the slide still unexplained at 16.9% cumulative; BHVN slipped a further 3.5%. Our search found no dated September 24 disclosures for any of the three as of roughly 8 pm ET.
NVO ADRs rose 1.2%, snapping three straight declines with EASD opening Monday; VERA added 0.9% and IONS eased 0.3% in sefaxersen session two; IMVT slipped 1.6%.
TLX closed at $11.31, 4.5% below the $11.841 scheme strike; the referendum stays unsettled after four flips in four sessions.
Still absent Thursday night, scopes per our searches: a Fayuvi pricing document, with $3.95 million WAC still only a call statement, and any Isembyld pricing primary.
No early CERVINO release surfaced through Thursday evening; the full etentamig data land today at the International Myeloma Society meeting.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The complete Viking offering table: shares, notes, the $50.75 conversion math, and the net proceeds construction
The InnoCare terms component by component, and how the $3.35 billion headline number is built
The REFOCUS and RADIANT data tables, straight from the FDA notice and Acadia's release
The full Thursday closing board with cause status on every move, plus the gauntlet week scoreboard
📋 The Week in Review
Monday: Grail's briefing documents posted with no major concerns and GRAL jumped 33.7%, Telix agreed to buy ITM for $1.65 billion upfront, and Novo fell 8% on its strategy day.
Tuesday: we read the FDA's documents, which put a 35.0% sensitivity question in front of the panel; Celldex fell again on a double Phase 3 win, and Viking jumped 35.7% on oral maintenance data.
Wednesday: the panel swept all three votes, 10 to 0 on safety, 6 to 4 on effectiveness, 7 to 2 with one abstention on benefit risk, with GRAL halted all session; Roche's sefaxersen hit in IgA nephropathy, and Immunovant exited cutaneous lupus.
Thursday: the settlement print, GRAL up 15.4% to $125.21; Viking priced $500 million and gave back 11.8%; Lilly signed InnoCare; Lyrfigtu became Korea's first FDA approved novel cancer drug; Acadia missed by six thousandths of a p value; Overton faced the Senate. Gauntlet events one and two delivered and paid. Event three, CERVINO, lands today.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 What $125.21 prices and what it cannot: the two variables left standing after the vote, and why the asymmetric risk in GRAL has moved from the tape to the label text
💊 The Viking read: what selling $500 million into a 35.7% rally says about the obesity financing window, where the $50.75 conversion strike draws management's line, and the IPO next in line to test the other end
📊 The China barbell: three deals in one day drew the map of what flows in and what gets sold, and the number that makes Boehringer's Shanghai exit the tell
🎯 Plus the full catalyst calendar, rebuilt after gauntlet week: the Galleri decision clock, CMS's November variable, EASD, and the Q4 queue
We spent a week saying the calendar would force the disclosures, and it did. We also said the rally had prepaid the vote, and Thursday charged another 15.4% for certainty. Both of those are results worth keeping. CERVINO prints today; we grade the full gauntlet Sunday night. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →